Roche Holding (NASDAQ:RHHBY) is scheduled to announce its Q4 earnings on January 31, and we expect the company to post steady top line and earnings growth, primarily led by Ocrevus. This relatively new drug has seen a strong growth in the recent quarters, and will likely generate $2 billion in ...
Roche Holding (NASDAQ:RHHBY) is scheduled to announce its Q4 earnings on January 31, and we expect the company to post steady top line and earnings growth, primarily led by Ocrevus. This relatively new drug has seen a strong growth in the recent quarters, and will likely generate $2 billion in ...
Share this Article
Recommended